万孚生物收盘下跌6.61%，滚动市盈率28.23倍，总市值111.50亿元

Group 1 - The core viewpoint of the articles highlights the performance and market position of Wanfang Biological, noting a significant decline in stock price and financial metrics [1][2] - As of August 20, Wanfang Biological's stock closed at 23.16 yuan, down 6.61%, with a rolling PE ratio of 28.23 times and a total market capitalization of 11.15 billion yuan [1] - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, placing Wanfang Biological at the 55th position within the industry [1][2] Group 2 - As of June 30, 2025, Wanfang Biological had 44,867 shareholders, an increase of 2,571 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on pregnancy, infectious disease, drug abuse, and chronic disease testing [1] - Wanfang Biological is recognized as a leading enterprise in the POCT field in China, holding various national and international certifications and accolades [1] Group 3 - The latest financial results for the first half of 2025 show that Wanfang Biological achieved a revenue of 1.246 billion yuan, a year-on-year decrease of 20.92%, and a net profit of 189 million yuan, down 46.82% year-on-year, with a gross profit margin of 62.87% [1]